The WeightExperts Approach — Treat the Person, Not the Scale

Why the method comes before the medication

A treatment is only as good as the goal it serves and the plan that sustains it, and the same tool can be excellent for one person and pointless for another. In our practice the sequence is therefore fixed: whether to treat, with what, and for how long is decided from this person's biology and health rather than from a scale reading. → Obesity as a Chronic Disease

Step 1 — Understand the person

Body weight is the output of a system with dozens of inputs, most of them invisible on a scale, so the history comes before the labs.

• Weight history — when weight changed, what was happening then, what was tried, and what drove any regain (usually a defended set point). → Why Is Weight So Hard to Lose?
• Medications — some antidepressants, antipsychotics, certain diabetes drugs, steroids, some beta-blockers and certain contraceptives promote weight gain. Often reversible, frequently missed.
• Sleep — short or disrupted sleep and untreated sleep apnea drive appetite and insulin resistance.
• Eating behavior — hunger versus reward eating, night eating, binge-eating disorder, restriction–binge cycles, which change what helps and what backfires. → Mental Health & Obesity
• Life context — work schedule, caregiving, food access, finances, stress, culture, all of which decide whether a plan is livable.
• Comorbidities and the patient's own goals.

Step 2 — Understand the biology

The same body weight can arise from very different physiology, and the physiology changes what works.

• Where the fat is. Visceral and ectopic fat, around organs and in the liver, is far more harmful than subcutaneous fat, so two people at the same BMI can carry very different risk. → BMI, Body Fat & Body Composition
• Metabolic health. Insulin resistance, prediabetes or diabetes, dyslipidaemia, blood pressure, and liver status — fat and fibrosis. → Obesity & Diabetes · Fatty Liver / MASLD
• Appetite and reward biology. Persistent hunger and food noise point to biology that responds to appetite-targeting medication. → Why Is Weight So Hard to Lose?
• Hormonal and genetic contributors. Thyroid disease rarely explains most of the weight; PCOS, cortisol excess and heritable susceptibility (roughly 40–70% heritability) all shape the picture. → Obesity & Hormones · Genetics of Obesity

In our practice the tests ordered are the ones that would change the plan. → Weight-Loss Lab Library

Step 3 — Define the goal, which is rarely "weight"

The scale is a crude proxy. Naming the health outcome changes how much loss is enough, which treatment fits, and what counts as success. Common goals:

• Type 2 diabetes remission or better control → Obesity & Diabetes
• Cardiovascular risk reduction — related to weight loss but not identical to it. → Obesity & Cardiovascular Health
• Fatty-liver disease — liver fat and, more importantly, fibrosis. → Fatty Liver / MASLD
• Obstructive sleep apnea — tirzepatide is now FDA-approved for moderate-to-severe OSA in adults with obesity.
• Mobility, joint pain and physical function
• Fertility, including PCOS-related infertility → PCOS & Weight
• Quality of life — energy, mood, participation, freedom from food preoccupation.

Even 5–10% sustained weight loss meaningfully improves glucose, blood pressure, lipids and liver fat. Health improves long before any "ideal" weight, and the threshold for "enough" differs between a goal of diabetes remission and one of fibrosis regression.

Step 4 — Choose appropriate treatment

Only now are tools selected, to fit the person, the biology and the goal. Behaviour is not virtuous and medication is not cheating; each is a means to a health end.

• Nutrition — not a single prescribed diet but the sustainable pattern that meets this person's needs and preferences. → Nutrition
• Physical activity and resistance training — for fitness, function and muscle preservation more than for scale weight. → Exercise, Muscle & Body Composition
• Behavioural support — eating patterns, sleep, stress and the psychology of change.
• Medication — GLP-1 and dual incretin therapies (semaglutide, tirzepatide) and others, where the disease and biology warrant them. → GLP-1 & Incretin Medications · Obesity Medication Library
• Combination — lifestyle plus medication is usually additive rather than either/or.
• Endoscopic options — for selected patients. → Endoscopic Obesity Treatment
• Bariatric/metabolic surgery — the most durable option, with ~25–30% total weight loss common and strong type 2 diabetes remission rates, carrying nutritional and follow-up obligations. → Bariatric Surgery

Matching matters more than potency: the strongest drug is of no use if it does not fit the goal, the biology or the life.

Step 5 — Preserve health during weight loss

Some of what is lost by any method is lean tissue; the aim is to lose excess fat while preserving functional lean mass. → GLP-1 & Muscle Loss

• Protein — adequate intake to defend lean mass in a calorie deficit.
• Resistance training — the most effective protection for muscle and strength. → Exercise, Muscle & Body Composition
• Micronutrients and bone — screened and supported, particularly after surgery, since bone density can fall with large losses.
• Liver — confirming that liver fat and fibrosis are improving, not only that weight is falling. → Fatty Liver / MASLD
• Psychological health — restriction–binge cycles, disordered eating and the emotional effects of rapid change. → Mental Health & Obesity

A lower DXA lean-mass number is not proof that a drug destroys muscle: lean mass includes water and organ mass, and some decline is expected when a large body gets smaller. Strength and function are what matter. → GLP-1 & Muscle Loss

Step 6 — Plan maintenance before starting

Stopping effective treatment predictably reverses much of its benefit: after semaglutide is withdrawn, people regain roughly two-thirds of lost weight within about a year, and the cardiometabolic gains reverse with it. A treatment that produces spectacular loss and is then stopped without a plan often ends where it began. → Weight Regain & Maintenance

The maintenance strategy is therefore designed before the loss phase, deciding in advance:

• What happens if a medication works — continue, taper or transition, and on what evidence.
• How lifestyle and monitoring will carry the maintenance load.
• What happens if weight creeps back — an adjustment to the plan rather than an assignment of blame.
• How to make the eventual weight sustainable rather than the lowest number achievable by effort.

Maintenance is a design constraint on the plan, not a later addition to it. → GLP-1 hub

Step 7 — Measure what matters

Measuring weight alone optimises for weight, sometimes at the expense of health. The outcomes tracked reflect the goal set in Step 3:

• Waist circumference — visceral fat, often more informative than BMI. → BMI, Body Fat & Body Composition
• Blood pressure
• A1c and glucose → Obesity & Diabetes
• Lipids — the atherogenic picture, not total cholesterol alone. → Obesity & Cardiovascular Health
• Liver — enzymes and, where relevant, FIB-4 and elastography, with fat and fibrosis measured separately. → Fatty Liver / MASLD
• Fitness and strength — both are powerful health predictors.
• Body composition — fat versus lean, not total mass.
• Quality of life, sleep and function — energy, mood, sleep apnea, mobility, food freedom.

When these markers improve, health improves — sometimes while the scale is stubborn.

What the evidence says about this approach

• What we know: obesity is chronic, relapsing and biologically defended; modest sustained loss improves multiple outcomes; behaviour, medication and surgery all have strong evidence; regain after stopping is predictable. Grade A 🟢
• What we think: matching treatment to the person, protecting muscle and planning maintenance in advance produce better long-term health than a scale-first approach. Grade B 🟡
• What we don't know: the ideal maintenance strategy after modern medications, and who can safely stop. Grade B 🟡
• What patients should do: define a health goal with a clinician, choose treatment matched to it, protect muscle, plan maintenance from the start, and judge success by health markers.

Questions patients ask

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: AACE/ACE adiposity-based chronic disease framework; Obesity Medicine Association clinical definition; AHA/ACC/TOS and Endocrine Society obesity management guidance; STEP and SURMOUNT programme data; Sumithran et al. (NEJM) on appetite hormones after weight loss. Educational; not individualized advice.